Dodge & Cox slightly bumped up its stake in Regeneron Pharmaceuticals, now holding a cool $1.65 billion in shares. This minor 0.4% increase added just 9,381 shares but upped their ownership to 2.11%.

FDA accepts Regeneron's sBLA for Eylea HD in RVO with priority review; QUASAR data supports monthly dosing, target action date set for August 2025.

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $831.43, with a high estimate of $1013.00 and a low estimate of $547.00. Highlighting a 8.86% ...

Pharmaceuticals announced that the U.S. Food and Drug Administration, FDA, has accepted for Priority Review the supplemental ...

Goldman Sachs dialed down its price target on Regeneron Pharmaceuticals, slicing it from $1,019 to $917, while still ...

We recently published a list of 12 Best Renewable Energy Stocks to Buy in 2025. In this article, we are going to take a look ...

With a market cap of $62.4 billion, Regeneron Pharmaceuticals, Inc. (REGN) discovers, invents, develops, manufactures, and ...

Regeneron's oncology platform is poised to be a significant growth driver in the next decade. Read why REGN stock remains a ...

The stock's fall snapped a two-day winning streak.

Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look ...

Looking back on immuno-oncology stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Regeneron ...

In a report released on April 11, Salveen Richter from Goldman Sachs maintained a Buy rating on Regeneron (REGN – Research Report), with a ...